Events & News

Jul 08,2026

From China's First Approved Stem Cell Therapy to Its First Exosome Therapeutic IND: CytoNiche Continues to Advance the Industrialisation of MSC-Derived Therapies

CytoNiche supports China's first exosome therapeutic IND, following its first approved stem cell therapy, advancing scalable MSC and exosome manufacturing.

Jul 02,2026

CytoNiche's Official Statement on the miniSPIN Series

The statement outlines CytoNiche's position on product authenticity, intellectual property, and authorised distribution, and provides guidance on identifying genuine 3D FloTrix™ miniSPIN™ series products.

May 26,2026

CytoNiche Successfully Conducts High DecaGiga Cell Manufacturing Masterclass

CytoNiche successfully conducted its High DecaGiga Cell Manufacturing Masterclass, advancing scalable and automated CGT manufacturing expertise.

Mar 12,2026

CytoNiche Receives Top Bioprocessing Honour at ABEA 2026

Cytoniche Honoured with "Emerging Bioprocessing Supplier Award: Downstream Processing" at ABEA 2026

Jan 22,2026

The Industrial Engine for NK Cell Therapy: Scaling NK Cell Therapy with 3D FloTrix™ NK Serum-Free Medium Kit (RNK59)

Unveiling the 3D FloTrix™ NK Serum Free Medium Kit, a serum-free, animal-origin-free, and antibiotic-free medium for scalable, GMP-ready NK cell manufacturing.

< 123 >